M. Docteur Jonathan ISRAEL

Bibliographie

• ARCANN : An Automated Fading event Classifier

  2025

  CongrèsKa & broadband Space communications and navigation conference 2025

• RAICE: Real-time Autoencoder for Indoor Coverage Estimation

  2025

  CongrèsURSI AP-RASC 2025

• AIRIS 2 : a Smart Gateway Diversity Algorithm for Very High-Throughput Satellite Systems

  2025

  ArticleIEEE Wireless Communications Letters

• Land Mobile Propagation Satellite Model based on 360° images

  2021

  CongrèsJournées d'études - propagation radioélectrique

• Validation of ITU-R P.833-9 tree attenuation model for Land Mobile Satellite propagation channel at Ku/Ka band

  2021

  CongrèsEUCAP 2021

• Propagation channel characterization for Ka mobile communication systems

  2020

  CongrèsEUCAP 2020

• A physical–statistical hybrid model for Land Mobile Satellite propagation channel at Ku/Ka band

  2020

  CongrèsEUCAP 2020

• SE-Workbench-RF: Performant and High-Fidelity Raw Data Generation for Various Radar Applications

  2019

  Congrès2019 20th International Radar Symposium (IRS)

Source : HAL — archive ouverte CCSD/CNRS (couvre articles, chapitres EMC, communications congrès, thèses).

Localisation

Adresses géocodées via la Base Adresse Nationale (api-adresse.data.gouv.fr). Précision indicative.

Lieux de consultation

• CABINET DU DR Jonathan ISRAEL

  9 RUE LEON VAUDOYER, 75007 Paris

  Libéral
  © OpenStreetMap

  📷 Street View ↗🗺️ Maps ↗OSM ↗

• GHU APHP CUP SITE COCHIN PORT ROYAL

  27 Rue DU FAUBOURG SAINT JACQUES, 75679 Paris 14e Arrondissement

  ☎ 0158414141Hospitalier🏥 Voir cet établissement

Tarifs & secteur de conventionnement

Prendre rendez-vous & contact

Lien Doctolib = recherche Google site:doctolib.fr (le 1er résultat est presque toujours le profil correct s'il existe).

Top publications · les plus citées

• 1

  Ketamine for the Treatment of Chronic Pain: A Comprehensive Review

  Health psychology research · 2021

  📚 28 citations🎯 RCR 2.53Top 20% NIH🔓 Open Access📄 PDF gratuit ↗

  Lire l'abstract Crossref ↓

  Background Chronic pain significantly worsens the quality of life. Unlike neuropathic, musculoskeletal, postoperative pain, and cancer pain, chronic primary pain cannot be explained by an underlying disease or condition, making its treatment arduous. Objectives This manuscript intends to provide a comprehensive review of the use of ketamine as a treatment option for specific chronic pain conditions. Study Design A review article. Setting A review of the literature. Methods A search was done on PubMed for relevant articles. Results A comprehensive review of the current understanding of chronic pain and the treatment of specific chronic pain conditions with ketamine. Limitations Literature is scarce regarding the use of ketamine for the treatment of chronic pain. Conclusion First-line treatment for many chronic pain conditions includes NSAIDs, antidepressants, anticonvulsants, and opioids. However, these treatment methods are unsuccessful in a subset of patients. Ketamine has been explored in randomized controlled trials (RCTs) as an alternative treatment option, and it has been demonstrated to improve pain symptoms, patient satisfaction, and quality of life. Conditions highlighted in this review include neuropathic pain, fibromyalgia, complex regional pain syndrome (CRPS), phantom limb pain (PLP), cancer pain, and post-thoracotomy pain syndrome. This review will discuss conditions, such as neuropathic pain, fibromyalgia, complex regional pain syndrome, and more and ketamine’s efficacy and its supplementary benefits in the chronic pain patient population. As the opioid crisis in the United States continues to persist, this review aims to understand better multimodal analgesia, which can improve how chronic pain is managed.

• 2

  A 26-Year Experience with Microsurgical Reconstruction of Hemifacial Atrophy and Linear Scleroderma

  Plastic and reconstructive surgery · 2018

  📚 27 citations🎯 RCR 3.01Top 16% NIH

  Lire l'abstract Crossref ↓

  Background: Parry Romberg disease (hemifacial atrophy) and linear scleroderma (coup de sabre) are progressive, usually unilateral facial atrophies of unknown cause. The gold standard treatment for these patients has been microsurgical reconstruction following the “burning out” of the facial atrophy and stable contour for 2 years. Methods: The authors report their experience treating patients with hemifacial atrophy and linear scleroderma with free tissue transfers between 1989 and 2016. A modified parascapular flap based on the circumflex scapular artery was most commonly used. Results: A total of 177 patients were included. The most common complication was hematoma, occurring in 12 patients (7 percent). Follow-up ranged from 1 to 26 years. All patients subjectively experienced improved facial symmetry and aesthetics. No disease process has recurred to date, even in cases of severe, progressive disease. Conclusions: In the authors’ experience, patients treated early in their disease course have immediate and sustained correction of their deformity, with slowing or in most cases cessation of the disease process following free tissue transfer. The authors now advocate for immediate reconstruction for active disease, especially in young children. CLINICAL QUESTIONS/LEVEL OF EVIDENCE: Therapeutic, IV.

• 3

  Baricitinib for the treatment of rheumatoid arthritis

  Reumatologia · 2020

  📚 22 citations🎯 RCR 1.26🔓 Open Access📄 PDF gratuit ↗

  Lire l'abstract Crossref ↓

  Rheumatoid arthritis (RA) is a common inflammatory disease with several implications on health, disability and economy. Conventional treatment for RA centers on anti-inflammatory drugs and specific targeting of tumor necrosis factor  (TNF-) and interleukin 6 (IL-6). Baricitinib is a novel, Food and Drug Administration (FDA) approved, once daily oral drug that is effective in combination with current treatment and results in significantly reduced symptoms with good safety profile. Further studies are required to find rare side effects and evaluate the long term efficacy in disease modulation and patient symptom reduction. This is a comprehensive review of the literature on baricitinib for the treatment of RA.<br /> This review provides an update on the pathophysiology, diagnosis and conventional treatment of RA, then proceeds to introduce baricitinib and the data that exists to support or refute its use in RA. The presented study also indicated clinical trials confirming the effectiveness of baricitinib in this indication.

Publications scientifiques (6) — classées par pathologie

Source PubMed · Recherche par auteur (homonymes possibles, vérifier l'affiliation).

Datasets & protocoles partagés

• Basic human values across the United States and their political, economic, social and health correlates

  StudyRegistration2021OSF Registries

  The present project combines spatially-aggregated larges-scale values data with an array of political, economic, social and health-related (PESH) state-level outcomes to conduct a systematic, theory-driven and pre-regist

Source : DataCite — DOIs pour datasets, logiciels, protocoles, registres patient. Hors articles (déjà couverts).

Partager cette fiche